The use of FK506 and RS61443 for reversal of small-bowel rejection

  • M. J. Stangl
  • C. Gräb
  • T. Fischer
  • H. Mebert
  • M. Weiß
  • C. Hammer
Conference paper

Abstract

Successful clinical small-bowel transplantation is still difficult to achieve [3,6]. Two features render the small intestine unique among vascularised solid organ grafts. First, the bowel contains a large amount of lymphoid tissue within the Peyer’s patches, mesenteric lymph nodes, and intraepithelial lymphocytes, which are thought to mediate graft-versus-host disease and provide a major stimulus for the recipient’s immune system [10]. Unfortunately, mere surgical reduction of these tissues, by using segmental allografts, does not furnish any immunological advantage [12]. Second, the small bowel lacks specific serum markers such as blood urea nitrogen (BUN) in the kidney or bilirubin in liver transplantation. Clinical signs such as fever, pain, or tenderness of the abdomen may indicate an already advanced destruction of the graft. Therefore, very potent immunosuppressive regimens are necessary to avoid small-bowel allograft rejection or even to reverse an ongoing rejection process. Cyclosporin was shown in small and large animal models to control rejection reactions sufficiently [4, 13]. However, there are two even more promising immunosuppressive agents currently under investigation. FK506, a macrolide lactone isolated from Streptomyces tsukubaensis, leads to long-term survival of small-bowel allografts in a rodent model and has already been used in a few clinical small-bowel transplantations [11,14]. RS61443, a mycophenolic acid morpholinoethylester, selectively inhibits T- and B-cell proliferation [9]. We have investigated the use of FK506 and RS61443 for the reversal of small-bowel allograft rejection in a small animal model.

Key words

FK506 RS61443 Small-bowel rejection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andersson J, Nagy S, Groth C, Andersson U (1991) Effects of FK 506 or cyclosporin A on cytokine production studied in vitro at a single cell level. First International Congress on FK506, Pittsburgh, Penn., August 21–24Google Scholar
  2. 2.
    Billingham RE, Medawar PB (1951) The technique of free skin grafting in mammals. J Exp Biol 28: 3Google Scholar
  3. 3.
    Deltz E, Schroeder P, Schweizer E, Gebhardt H, Gundlach M, Hansmann ML, Leimenstoll G (1991) Experimental fundamentals and first clinical experiences in small bowel transplantation. Eur Surg Res 23:130Google Scholar
  4. 4.
    Diliz-Perez HS, McClure J, Bedetti C, Hong HQ, de Santibanes E, Shaw B W, van Thiel D, Iwatsuki S, Starzl TE (1984) Successful small bowel allotransplantation in dogs with cyclosporine and prednisone. Transplantation 37 (2): 126–129PubMedCrossRefGoogle Scholar
  5. 5.
    Franklin TJ, Cook JM (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113:515PubMedGoogle Scholar
  6. 6.
    Goulet O, Revillon Y, Jan D, Brousse N, Ricour C (1991) Small bowel transplantation in children. Eur Surg Res 23:130–131Google Scholar
  7. 7.
    Hoffman AL, Makowka L, Banner B, Cai X, Cramer DV, Pascualone A, Todo S, Starzl TE (1990) The use of FK 506 for small intestine allotransplantation. Transplantation 49:483–490PubMedCrossRefGoogle Scholar
  8. 8.
    Mong S (1991) Preclinical toxicolocy of FK 506. First International Congress on FK 506, Pittsburgh, Penn., August 21–24Google Scholar
  9. 9.
    Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC (1990) Mycophenolic acid morpholinoethylester (RS 61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22 (4): 1659–1662PubMedGoogle Scholar
  10. 10.
    Snell GD (1957) The homograft reaction. Ann Rev Microbiol 11: 439CrossRefGoogle Scholar
  11. Stangl MJ, Lee KKW, Starzl T, Land W, Schraut WH (1990) Specific tolerance induction with FK506 after allogeneic small bowel transplantation. Langenbecks Arch Chir 323–326Google Scholar
  12. 12.
    Stangl MJ, Schraut WH, Moynihan HL, Lee T (1989) Rejection of ileal versus jejunal allografts. Transplantation 47:424–427PubMedCrossRefGoogle Scholar
  13. 13.
    Stangl MJ, Schraut WH, Moynihan HL, Lee TK, Lee KKW (1990) Effect of cyclosporine therapy in controlling the rejection of ileal versus jejunal allografts. Transplant Int 3:149–155Google Scholar
  14. 14.
    Todo S, Tzakis A, Fung J, Abu-Elmagd K, Reyes J, van Thiel D, Starzl T (1991) Clinical small bowel transplantation under FK506. First International Congress on FK506, Pittsburgh, Penn., August 21–24Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. J. Stangl
    • 1
  • C. Gräb
    • 2
  • T. Fischer
    • 2
  • H. Mebert
    • 2
  • M. Weiß
    • 3
  • C. Hammer
    • 2
  1. 1.Chirurgische Klinik und Poliklinik der LMU MünchenKlinikum GroßhadernMünchenGermany
  2. 2.Institut für Chirurgische Forschung der LMU MünchenMünchenGermany
  3. 3.Institut für Pathologie der LMU MünchenMünchenFederal Republic of Germany

Personalised recommendations